Filing Flows › ImmunityBio (IBRX) › Recalls, complaints & regulation
ImmunityBio (IBRX): EPA violations and clinical trials
ImmunityBio (IBRX) beyond its filings: 1 EPA-regulated facility in violation, no penalties in five years; 22 active clinical trials.
EPA facilities in violation
| Facility (as registered) | City | Status | Penalties |
|---|---|---|---|
| IMMUNITYBIO, INC. | Dunkirk, NY | Significant Violation | — |
Facilities in the EPA's ECHO register whose registered name matches the company's; a facility can belong to another business of the same name.
ImmunityBio's latest quarter
ImmunityBio, Q2 2026: revenue $51.2M (+94% year over year), operating margin -120.4%, net loss $230M, operating cash flow −$66.5M. The chart follows the revenue to costs, profit and cash.
Questions
Has ImmunityBio been fined by the EPA?
The 6 EPA-regulated facilities on file under its name drew no penalties in five years; 1 is in violation now.
How many clinical trials does ImmunityBio have?
22 active studies on ClinicalTrials.gov, 2 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.